Ondine Biomedical, Inc. (OBI) AI Stock Analysis

• Market Cap: £71.28M
• Dividend Yield: N/A
• Average Volume (3M): 476.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 63.25%
• EPS Growth: 8.94%
• Country: UK
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 518,366,940
• 10 Day Avg. Volume: 292,699
• 30 Day Avg. Volume: 476,744
• PEG Ratio: 0.53
• Price to Book (P/B): 6.29
• Price to Sales (P/S): 21.10
• P/FCF Ratio: -2.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £13.50
• Price Target Upside: -1.82% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: 13.50p ▼(-1.82% Downside)

Ondine Biomedical, Inc. faces significant challenges with profitability and cash flow, which are the most impactful factors in the overall score. The technical indicators suggest bearish momentum, and the valuation metrics are poor due to negative earnings. The absence of earnings call insights and corporate events means these factors do not influence the score.

Ondine Biomedical, Inc. Business Overview & Revenue Model

Company Description

Ondine Biomedical, Inc. (OBI) is a biotechnology company focused on developing and commercializing innovative antimicrobial technologies to combat infections in healthcare. The company operates primarily within the medical device and healthcare sectors, offering advanced products that utilize photodisinfection technology to effectively reduce infectious pathogens. OBI's flagship product, the Steriwave system, is designed for use in various clinical settings, including wound care, surgery, and dental applications, providing a non-invasive solution that enhances patient safety and treatment outcomes.

How the Company Makes Money

Ondine Biomedical generates revenue through the sale of its medical devices and systems, particularly the Steriwave system, to hospitals, clinics, and healthcare providers. The company may also engage in partnerships with healthcare organizations and distributors to expand its market reach and facilitate product adoption. Additionally, OBI could explore revenue streams through licensing agreements or collaborations with research institutions, enabling further development of its technologies while securing additional funding and resources.

Ondine Biomedical, Inc. Financial Statement Overview

Summary

Ondine Biomedical, Inc. shows strong revenue growth but faces significant challenges with profitability and cash flow. The low leverage provides financial flexibility, but operational inefficiencies and negative cash flow are major concerns.

Income Statement

Ondine Biomedical, Inc. shows significant revenue growth of 70.94% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins, which reflect ongoing operational challenges. The gross profit margin is relatively healthy at 64.47%, but the negative net income suggests high costs or inefficiencies.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.024, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the available data suggests a moderate level of equity relative to assets.

Cash Flow

Ondine Biomedical, Inc. has a negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is close to 1, indicating that free cash flow is aligned with net income, albeit both are negative. The company needs to improve its cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.63M	2.05M	1.20M	638.00K	2.57M	1.79M
Gross Profit	433.01K	1.32M	703.00K	287.00K	1.25M	649.00K
EBITDA	-13.93M	-18.49M	-13.79M	-18.85M	-48.36M	-14.56M
Net Income	-14.26M	-19.10M	-14.41M	-19.37M	-50.09M	-16.27M
Balance Sheet
Total Assets	4.03M	12.82M	5.73M	16.57M	34.14M	2.63M
Cash, Cash Equivalents and Short-Term Investments	1.22M	9.77M	2.98M	13.13M	30.36M	626.00K
Total Debt	351.00K	168.00K	541.00K	896.00K	739.00K	31.46M
Total Liabilities	4.01M	5.95M	3.65M	4.92M	4.48M	36.46M
Stockholders Equity	19.00K	6.88M	2.08M	11.64M	29.66M	-33.81M
Cash Flow
Free Cash Flow	-5.27M	-15.50M	-13.83M	-16.66M	-12.62M	-6.43M
Operating Cash Flow	-12.40M	-15.49M	-13.65M	-16.34M	-12.54M	-6.33M
Investing Cash Flow	-10.07K	-10.00K	-177.00K	-311.00K	-77.00K	2.90M
Financing Cash Flow	9.28M	21.74M	3.79M	-275.00K	41.90M	3.83M

Ondine Biomedical, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Neutral. The current price of 13.75 is below the 20-day moving average (MA) of 14.72, below the 50-day MA of 14.79, and above the 200-day MA of 11.79, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.57 is Neutral, neither overbought nor oversold. The STOCH value of 16.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:OBI.

Ondine Biomedical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	49 Neutral	£7.19M	―	-5.41%	―	-20.31%	-19.35%
SAR	47 Neutral	£32.45M	―	-87.30%	―	―	71.17%
OBI	41 Neutral	£71.28M	―	-430.02%	―	63.25%	8.94%
SBTX	40 Underperform	£38.49M	―	-63.28%	―	1557.07%	24.70%